A multicenter phase II study to evaluate safety and efficacy of glutadon once weekly (GDO) in patients with metastatic colorectal cancer resistant or intolerable to approved chemo- and molecular-targeted therapies

开始日期2010-10-05

申办/合作机构

New Medical Enzymes Ag

100 项与 PEG-glutaminase/Diazo-oxo-L-norleucine 相关的临床结果

登录后查看更多信息

100 项与 PEG-glutaminase/Diazo-oxo-L-norleucine 相关的转化医学

登录后查看更多信息

100 项与 PEG-glutaminase/Diazo-oxo-L-norleucine 相关的专利（医药）

登录后查看更多信息

项与 PEG-glutaminase/Diazo-oxo-L-norleucine 相关的文献（医药）

2018-09-01·Journal of Materials Science: Materials in Medicine3区 · 工程技术

Fabrication of chitosan based nanocomposite with legumain sensitive properties using charge driven self-assembly strategy

3区 · 工程技术

Article

作者: Lin, Sen ; Wang, Dongmei ; Li, Qing ; Wang, Jingjie ; Ge, Chaoxiang ; Nan, Kaihui ; Luo, Mengmeng

Chitosan (CS) based nanoparticles (NPs) have several advantages in delivering drugs. They are usually prepared in a micro-emulsion solvent system but this route can leave significant levels of potentially harmful organic solvent residue in the NPs. In this study, we prepared CS based nanocomposites using charge driven self-assembly in an aqueous buffer, thus avoiding the use of organic solvents. Doxorubicin (DOX) was covalently attached to positive charged CS with a legumain substrate peptide to confer targeted drug release property, since legumain is often overexpressed in tumors or tumor associated micro environments. This DOX prodrug solution interacted with negative charged methoxyl poly (ethylene glycol)-block-poly (glutamic acid) copolymer (PEG-PGA) in an aqueous buffer forming nanocomposite with a regular morphology. The particle size and zeta potential of these NPs was regulated by the addition of different PEG-PGA concentrations into the DOX prodrug solution. Due to its potential for legumain triggered release, this DOX NP exhibited enhanced cytotoxicity against choroidal melanoma cell line (Mum-2C) and reduced cytotoxicity on normal human corneal epithelial cells (HCEC), suggesting a good potential for enhanced targeted delivery of chemotherapeutic agents. A chitosan based nanocomposite with legumain sensitive properties are rapidly controllable prepared in aqueous buffer by charge driven self-assembly strategy, without using micro-emulsion solvent system and cross-linking agents.

100 项与 PEG-glutaminase/Diazo-oxo-L-norleucine 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
结直肠癌	临床2期	波兰	New Medical Enzymes Ag	-
结直肠癌	临床2期	德国	New Medical Enzymes Ag	-
非小细胞肺癌	临床2期	波兰	New Medical Enzymes Ag	-
非小细胞肺癌	临床2期	波兰	New Medical Enzymes Ag	-
非小细胞肺癌	临床2期	-	New Medical Enzymes Ag	-
非小细胞肺癌	临床2期	德国	New Medical Enzymes Ag	-
非小细胞肺癌	临床2期	德国	New Medical Enzymes Ag	-
非小细胞肺癌	临床2期	-	New Medical Enzymes Ag	-
胃癌	临床2期	德国	New Medical Enzymes Ag	-
胃癌	药物发现	德国	New Medical Enzymes Ag	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ASCO2011	临床1期	HR阳性/HER2低表达实体瘤	16	PEG-PGA	(憲築淵壓選構網衊範鹹) = 繭遞鬱糧觸窪鹹築憲醖獵獵製遞艱窪鑰淵構鏇 (構襯遞淵憲範齋構艱願 )	-	2011-05-20
ASCO2008	临床2期	实体瘤	-	PEG-PGA	(觸願夢鑰糧廠膚鹹餘襯) = 醖遞繭艱窪積觸積築遞觸顧廠艱齋壓醖觸鹽艱 (糧壓餘顧齋糧顧願繭網 ) 更多	-	2008-05-20
ASCO2007	临床1期	难治恶性实体肿瘤	-	PEG-PGA	繭範窪餘襯艱艱壓鏇糧(鑰簾願淵遞繭蓋夢範簾) = 廠網廠製獵襯顧醖網糧範夢鑰衊範夢壓製餘醖 (構夢積鹽製獵積廠襯選 ) 更多	-	2007-06-20
ASCO2007	临床1期	难治恶性实体肿瘤	-	DON	繭範窪餘襯艱艱壓鏇糧(鑰簾願淵遞繭蓋夢範簾) = 夢窪廠選醖鏇網襯遞積範夢鑰衊範夢壓製餘醖 (構夢積鹽製獵積廠襯選 )	-	2007-06-20